The purpose of this review is to describe dilemmas associated with antibiotic collateral damage and provide clinical pharmacists with information to improve antibiotic utilization. The clinical use of antibiotics has been associated with acquisition and spread of nosocomial pathogens and multidrug-resistant strains, such as extended-spectrum beta-lactamases, AmpC hyper-producers, carbapenemases, and resistant gram-positive organisms. The mobility of plasmid-mediated resistance, such as extended-spectrum beta-lactamases and the more recently isolated Klebsiella pneumoniae carbapenemases, have been well-demonstrated with worldwide distribution across several different species. The challenges surrounding antibiotic-associated diarrhea, particularly Clostridium difficile infection (CDI), continue to evolve with outbreaks of hypervirulent strains linked to the use of less commonly implicated antibiotics. Published literature was searched and reviewed using PubMed. Undesirable attributes related to antibiotic use can have broad consequences in addition to their effect on individual patients. This collateral damage can evolve over time, and prescribers must be aware of current concerns and be diligent in their judicious use of antibiotics.
YamF.K., SmithK.M.“Collateral damage”: antibiotics and the risk of Clostridium difficile infection. Orthopedics.2005; 28(3): 275–279.
4.
CosgroveS.E., QiY., KayeK.S., HarbarthS., KarchmerA.W., CarmeliY.The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol.2005; 26(2): 166–174.
5.
SchwaberM.J., Navon-VeneziaS., KayeK.S., Ben-AmiR., SchwartzD., CarmeliY.Clinical and economic impact of bacteremia with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother.2006; 50(4): 1257–1262.
6.
KwonK.T., OhW.S., SongJ.H.Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother.2007; 59(3): 525–530.
ChaïbiE.B., SirotD., PaulG., LabiaR.Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother.1999; 43(4): 447–458.
9.
BonnetR.Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother.2004; 48(1): 1–14.
10.
SchneiderI., QueenanA.M., MarkovskaR., MarkovaB., KeuleyanE., BauernfeindA.New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238-Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. Antimicrob Agents Chemother.2009; 53(10): 4518–4521.
NordmannP., CuzonG., NaasT.The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis.2009; 9(4): 228–236.
13.
YongD., TolemanM.A., GiskeC.G., ChoH.S., SundmanK., LeeK., WalshT.R.Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother.2009; 53(12): 5046–5054.
SandersC.C., SandersW.E.Jr.Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis.1986; 154(5): 792–800.
16.
SiberryG.K., TekleT., CarrollK., DickJ.Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis.2003; 37(9): 1257–1260.
17.
ColodnerR., RockW., ChazanB.Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in non-hospitalized patients. Eur J Clin Microbiol Infect Dis.2004; 23(3): 163–167.
18.
ZaoutisT.E., GoyalM., ChuJ.H.Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics.2005; 115(4): 942–949.
19.
HarrisA.D., McGregorJ.C., JohnsonJ.A.Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis.2007; 13(8): 1144–1149.
20.
HuangY., ZhuangS., DuM.Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China. Infection.2007; 35(5): 339–345.
21.
YangK., GuglielmoB.J.Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother.2007; 41(9): 1427–1435.
22.
GniadkowskiM.Evolution of extended-spectrum beta-lactamases by mutation. Clin Microbiol Infect.2008; 14(Suppl 1): 11–32.
23.
FalagasM.E., RafailidisP.I., KofteridisD.Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother.2007; 60(5): 1124–1130.
24.
AragónL.M., MirelisB., MiróE.Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY- type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases. J Antimicrob Chemother.2008; 61(5): 1029–1032.
25.
MendonçaN., FerreiraE., LouroD., ARSIP Participants, CaniçaM.Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in Portugal. Int J Antimicrob Agents.2009; 34(1): 29–37.
26.
BushK.Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect.2008; 14(Suppl 1): 134–143.
27.
Ben-AmiR., Rodríguez-BañoJ., ArslanH.A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in non-hospitalized patients. Clin Infect Dis.2009; 49(5): 682–690.
28.
NovaisA., CantónR., CoqueT.M., MoyaA., BaqueroF., GalánJ.C.Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance. Antimicrob Agents Chemother.2008; 52(7): 2377–2382.
29.
DashtiA.A., JadaonM.M., AmyesS.G.Retrospective study of an outbreak in a Kuwaiti hospital of multidrug-resistant Klebsiella pneumoniae possessing the new SHV-112 extended-spectrum beta-lactamase. J Chemother.2010; 22(5): 335–338.
30.
LeeS.Y., KotapatiS., KutiJ.L., NightingaleC.H., NicolauD.P.Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol.2006; 27(11): 1226–1232.
31.
SongK.H., JeonJ.H., ParkW.B.Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis.2009; 9: 41.
32.
KitzisM.D., FerréB., CoutrotA., AcarJ.F., GutmannL.In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria. Eur J Clin Microbiol Infect Dis.1989; 8(9): 783–788.
33.
LivermoreD.M.Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol.1987; 6(4): 439–445.
34.
ChowJ.W., FineM.J., ShlaesD.M.Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med.1991; 115(8): 585–590.
35.
ChoiS.H., LeeJ.E., ParkS.J.Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother.2008; 52(3): 995–1000.
36.
LautenbachE., SynnestvedtM., WeinerM.G.Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol.2010; 31(1): 47–53.
37.
HusseinK., SprecherH., MashiachT., OrenI., KassisI., FinkelsteinR.Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol.2009; 30(7): 666–671.
38.
KwakY.G., ChoiS.H., ChooE.J.Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist.2005; 11(2): 165–169.
39.
PatelG., HuprikarS., FactorS.H., JenkinsS.G., CalfeeD.P.Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol.2008; 29(12): 1099–1106.
40.
YigitH., QueenanA.M., AndersonG.J.Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother.2001; 45(4): 1151–1161.
41.
BratuS., MootyM., NichaniS.Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother.2005; 49(7): 3018–3020.
42.
VillegasM.V., LolansK., CorreaA., KattanJ.N., LopezJ.A., QuinnJ.P.Colombian Nosocomial Resistance Study Group. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother.2007; 51(4): 1553–1555.
43.
BoucherH.W., TalbotG.H., BradleyJ.S.Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis.2009; 48(1): 1–12.
44.
GiamarellouH., PoulakouG.Multidrug-resistant Gram-negative infections: what are the treatment options?Drugs.2009; 69(14): 1879–1901.
45.
KumarasamyK.K., TolemanM.A., WalshT.R.Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis.2010; 10(9): 597–602.
46.
Centers for Disease Control and Prevention (CDC).Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep.2010; 59(24): 750.
47.
LeclercqR., DerlotE., DuvalJ., CourvalinP.Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med.1988; 319(3): 157–161.
48.
Recommendations for preventing the spread of vancomycin resistance.Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep.1995; 44(RR12): 1–13.
49.
SievertD.M., RudrikJ.T., PatelJ.B., McDonaldC., WilkinsM.J., HagemanJ.C.Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis.2008; 46(5): 668–674.
LeBlancL., PépinJ., ToulouseK.Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis.2006; 12(9): 1398–1405.
52.
Madaras-KellyK.J., RemingtonR.E., LewisP.G., StevensD.L.Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol.2006; 27(2): 155–169.
53.
WeberS.G., GoldH.S., HooperD.C., KarchmerA.W., CarmeliY.Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis.2003; 9(11): 1415–1422.
54.
GraffunderE.M., VeneziaR.A.Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother.2002; 49(6): 999–1005.
55.
MutoC.A., JerniganJ.A., OstrowskyB.E.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol.2003; 24(5): 362–386.
56.
ChengV.C., LiI.W., WuA.K.Effect of antibiotics on the bacterial load of methicillin-resistant Staphylococcus aureus colonization in anterior nares. J Hosp Infect.2008; 70(1): 27–34.
57.
RahalJ.J., UrbanC., HornD.Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA.1998; 280(14): 1233–1237.
58.
FurtadoG.H., PerdizL.B., SantanaI.L.Impact of a hospital-wide antimicrobial formulary intervention on the incidence of multidrug-resistant gram-negative bacteria. Am J Infect Control.2008; 36(9): 661–664.
59.
CharbonneauP., ParientiJ.J., ThibonP.Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis.2006; 42(6): 778–784.
60.
TedescoF.J., BartonR.W., AlpersD.H.Clindamycin-associated colitis. A prospective study. Ann Intern Med.1974; 81(4): 429–433.
61.
HogenauerC., HammerH.F., KrejsG.J.Mechanisms and management of antibiotic associated diarrhea. Clin Infect Dis.1998; 27(4): 702–710.
62.
Van AsscheG., DepoortereI., ThijsT.Contractile effects and intracellular Ca2+ signaling induced by motilin and erythromycin in the circular smooth muscle of human colon. Neurogastroenterol Motil.2001; 13(1): 27–35.
63.
DiveA., MiesseC., GalantiL.Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Crit Care Med.1995; 23(8): 1356–1362.
64.
AnneseV., JanssensJ., VantrappenG.Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology.1992; 102(3): 823–828.
65.
HenryD.C., RifferE., SokolW.N.Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother.2003; 47(9): 2770–2774.
66.
TurckD., BernetJ.P., MarxJ.Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr.2003; 37(1): 22–26.
67.
BartlettJ.G.Clinical practice. Antibiotic-associated diarrhea. N Engl J Med.2002; 346(5): 334–339.
68.
SethiS., BretonJ., WynneB.Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillinclavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother.2005; 49(1): 153–60.
69.
FileT.M.Jr, LodeH., KurzH., KozakR., XieH., BerkowitzE.600 Study Group. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother.2004; 48(9): 3323–3331.
70.
SmithC.J., BryantM.P.Introduction to metabolic activities of intestinal bacteria. Am J Clin Nutr.1979; 32(1): 149–157.
71.
DonskeyC.J.The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis.2004; 39(2): 219–226.
72.
YoungV.B., SchmidtT.M.Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol.2004; 42(3): 1203–1206.
73.
EdwardsC.A., DuerdenB.I., ReadN.W.Effect of clindamycin on the ability of a continuous culture of colonic bacteria to ferment carbohydrate. Gut.1986; 27(4): 411–417.
74.
ClimoM.W., IsraelD.S., WongE.S., WilliamsD., CoudronP., MarkowitzS.M.Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med.1998; 128(12 part 1): 989–995.
75.
KyneL., MerryC., O'ConnellB., HarringtonP., KeaneC., O'NeillD.Simultaneous outbreaks of two strains of toxigenic Clostridium difficile in a general hospital. J Hosp Infect.1998; 38(2): 101–112.
76.
McFarlandL.V., SurawiczC.M., StammW.E.Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis.1990; 162(3): 678–684.
77.
PépinJ., SahebN., CoulombeM.A.Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis.2005141: 1254–1260.
78.
LooV.G., PoirierL., MillerM.A.A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med.2005; 353(23): 2442–2449.
79.
MutoC.A., PokrywkaM., ShuttK.A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol.2005; 26(3): 273–280.
80.
DebastS.B., VaessenN., ChoudryA., Wiegers-LigtvoetE.A., van den BergR.J., KuijperE.J.Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect.2009; 15(5): 427–434.
81.
KyneL., HamelM.B., PolavaramR., KellyC.P.Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis.2002; 34(3): 346–353.
HalseyJ.Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm.2008; 65(8): 705–715.
84.
LefflerD.A., LamontJ.T.Treatment of Clostridium difficile-associated disease. Gastroenterology.2009; 136(6): 1899–1912.
85.
NelsonR.L.Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev.2007; 3: CD004610. doi: 10.1002/14651858.
86.
ZarF.A., BakkanagariS.R., MoorthiK.M., DavisM.B.A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis.2007; 45: 302–307.
87.
CohenS.H., GerdingD.N., JohnsonS.Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol.2010; 31(5): 431–455.
88.
Al-NassirW.N., SethiA.K., NerandzicM.M., BobulskyG.S., JumpR.L., DonskeyC.J.Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis.2008; 47(1): 56–62.
89.
McDonaldL.C., KillgoreG.E., ThompsonA.An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med.2005; 353(23): 2433–2441.
90.
WarnyM., PepinJ., FangA.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet.2005; 366(9491): 1079–1084.
91.
KenneallyC., RosiniJ.M., SkrupkyL.P.Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest.2007; 132(2): 418–424.
92.
ZilberbergM.D., ShorrA.F., KollefM.H.Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerging Infect Dis.2008; 14(6): 929–931.
93.
PépinJ., ValiquetteL., CossetteB.Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ.2005; 173(9): 1037–1042.
94.
NairS., YadavD., CorpuzM., PitchumoniC.S.Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol.1998; 93(10): 1873–1876.
95.
ModenaS., GollamudiS., FriedenbergF.Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol.2006; 40(1): 49–54.
96.
JohnsonS., HomannS.R., BettinK.M.Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med.1992; 117(4): 297–302.
97.
Al-NassirW.N., SethiA.K., LiY., PultzM.J.Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother.2008; 52(7): 2403–2406.
98.
CarlingP., FungT., KillionA., TerrinN., BarzaM.Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol.2003; 24(9): 699–706.
99.
Wong-BeringerA., NguyenL.H., LeeM., ShrinerK.A., PallaresJ.An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy.2009; 29(6): 736–743.
100.
DellitT.H., OwensR.C., McGowanJ.E.Jr; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis.2007; 44(2): 159–177.
101.
ArnoldS.R., StrausS.E.Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev.2005; 4: CD003539. doi: 10.1002/14651858.
102.
BelongiaE.A., KnoblochM.J., KiekeB.A., DavisJ.P., JanetteC., BesserR.E.Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis.2005; 11(6): 912–920.
103.
WyattJ.C., Paterson-BrownS., JohansonR.Randomised trial of educational visits to enhance use of systematic reviews in 25 obstetric units. BMJ.1998; 317(7165): 1041–1046.
